Category
All
New Technology
Service & Software
Internet & Communication
Electronics & Semiconductor
Pharma & Healthcare
Other
Energy & Power
Agriculture
Consumer Goods
Machinery & Equipment
Food & Beverages
Medical Care
Automobile & Transportation
Packaging
Chemical & Material
Medical Devices & Consumables
Category
All
Total: 4 records, 1 pages
Search For: Afatinib Dimaleate
Global Afatinib Dimaleate Supply, Demand and Key Producers, 2024-2030
11 Feb 2024
Pharma & Healthcare
The global Afatinib Dimaleate market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
Global Afatinib Dimaleate Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
16 Jan 2024
Pharma & Healthcare
According to our (Global Info Research) latest study, the global Afatinib Dimaleate market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
Global Afatinib Dimaleate Market 2024 by Company, Regions, Type and Application, Forecast to 2030
09 Jan 2024
Pharma & Healthcare
According to our (Global Info Research) latest study, the global Afatinib Dimaleate market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
Global Afatinib Dimaleate Market 2023 by Company, Regions, Type and Application, Forecast to 2029
11 Jan 2023
Pharma & Healthcare
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
USD3480.00
Add To Cart
Popular Product Keywords
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
Search For: Afatinib Dimaleate
Total: 4 records, 1 pages
The global Afatinib Dimaleate market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
According to our (Global Info Research) latest study, the global Afatinib Dimaleate market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
According to our (Global Info Research) latest study, the global Afatinib Dimaleate market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
USD3480.00
Add To Cart
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>